According to Dividend Channel, in trading on Wednesday, shares of PDL BioPharma Inc (PDLI) were yielding above the 10% mark based on its quarterly dividend (annualized to $0.60), with the stock changing hands as low as $5.90 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the iShares Russell 3000 ETF (IWV) back on 5/31/2000 — you would have paid $78.27 per share. Fast forward to 5/31/2011 and each share was worth $80.78 on that date, a mere $2.51 or 3.2% increase over eleven years. But now consider that you collected a whopping $9.69 per share in dividends over the same period, increasing your return to 20.27%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.7%; so by comparison collecting a yield above 10% would appear considerably attractive if that yield is sustainable. PDL BioPharma Inc (PDLI) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of PDL BioPharma Inc, looking at the history chart for PDLI below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 10% annual yield.
PDLI operates in the Biotechnology sector, among companies like Enzon Pharmaceuticals Inc (ENZN) which is up about 0.1% today, and Spectrum Pharmaceuticals Inc (SPPI) trading higher by about 4.4%. Below is a three month price history chart comparing the stock performance of PDLI, versus ENZN and SPPI.